Moxisylyte
 | |
| Clinical data | |
|---|---|
| Other names | Thymoxamine |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.186 |
| Chemical and physical data | |
| Formula | C16H25NO3 |
| Molar mass | 279.380 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction.[1] It is an α1-adrenergic antagonist.[2] In the United Kingdom, Moxisylyte is marketed as Opilon (Archimedes Pharma UK Ltd) and is used for the short-term treatment of primary Raynaud's syndrome. This is a condition where the fingers and toes become discoloured and is triggered by responses to cold, or emotional distress. Opilon tablets help by improving blood circulation to the extremities.[3][4]
References
- ^ British National Formulary 69, Chapter2.6.4, page 142
- ^ Sakakibara R, Hattori T, Uchiyama T, et al. (March 2000). "Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte". J. Auton. Nerv. Syst. 79 (2–3): 191–5. doi:10.1016/S0165-1838(99)00105-8. PMID 10699651.
- ^ British National Formulary 70, page 205
- ^ "Opilon tablets - Patient Information Leaflet (PIL) - (eMC)". www.medicines.org.uk.